Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abacavir hypersensitivity reaction.

Ross G Hewitt1

  • 1Departments of Medicine and Pharmacy Practice, State University of New York, Buffalo, NY, 14215, USA. rhewitt@buffalo.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|March 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rapid CD4 + T-lymphocyte decline and human immunodeficiency virus progression in females compared to males.

Scientific reports·2020
Same author

Enhanced care coordination improves HIV viral load suppression rates.

The American journal of managed care·2019
Same author

Life stress and adherence to antiretroviral therapy among HIV-positive individuals: a preliminary investigation.

AIDS patient care and STDs·2005
Same author

The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.

Journal of clinical pharmacology·2004
Same author

Human immunodeficiency virus-associated nephropathy: a primary care perspective.

Archives of internal medicine·2004
Same author

Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy.

Immunological investigations·2003
Same journal

Understanding the Clone-Censor-Weight Method in Observational Studies of Antibiotic Duration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Protection Against Recurrent Typhoid Fever Conferred by a Prior Episode: Evidence from a Large Cohort Study in Dhaka, Bangladesh.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Abacavir hypersensitivity reactions affect 3.7% of patients starting combination antiretroviral therapy. This immune reaction, poorly understood, necessitates abacavir discontinuation and avoidance of re-challenge due to severe risks.

Area of Science:

  • Pharmacology
  • Immunology
  • Infectious Diseases

Background:

  • Abacavir is an essential component of combination antiretroviral therapy (cART).
  • Hypersensitivity reactions (HSRs) to abacavir occur in a subset of patients.
  • The underlying mechanisms of abacavir-induced HSRs remain incompletely understood.

Purpose of the Study:

  • To summarize the incidence, risk factors, clinical presentation, and management of abacavir hypersensitivity.
  • To highlight the importance of recognizing and managing abacavir HSRs in HIV-infected individuals.

Main Methods:

  • Review of existing literature on abacavir hypersensitivity.
  • Analysis of clinical data regarding abacavir-associated adverse events.

Main Results:

Related Experiment Videos

  • Abacavir hypersensitivity reactions are estimated to occur in approximately 3.7% of patients initiating abacavir therapy.
  • Risk factors suggest differential susceptibility, with White patients at higher risk and patients of African descent at lower risk.
  • Altered drug metabolism and immune dysfunction are implicated as potential causes of abacavir HSRs.

Conclusions:

  • Clinical management primarily involves supportive care and immediate discontinuation of abacavir.
  • Re-challenge with abacavir in sensitized patients is strongly contraindicated due to the potential for severe, life-threatening reactions.
  • Further research is needed to elucidate the precise mechanisms of abacavir hypersensitivity.